Covance Expands Global Biologics Capabilities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Covance Expands Global Biologics Capabilities


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 4

Covance, a drug development services company, reported the expansion of large molecule bioanalytical space and the addition of new members to its biologics team.

The additional space will be added at its central laboratory facility in Indianapolis, Ind. The expansion, which is planned to open during the second half of 2014, will double the company’s large molecule capacity and is expected to add approximately 100 new positions over the next five years.

In addition to the expansion, the company also appointed Mike Holsapple, PhD, as Covance’s executive director of global immunotoxicology. Holsapple is a member of the Academy of Toxicological Sciences and past president of the Society of Toxicology, with more than 30 years of experience.

Source: Covance

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here